Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 24, 2007. The report details a share repurchase transaction executed in accordance with authority granted by shareholders at the Annual General Meeting held on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 2,985,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,331.49 pence per share.
- Treasury Holdings: 302,517,678 shares (representing 5.02% of total voting rights).
- Shares in Issue: 5,717,771,304 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 2,985,000 shares for Treasury. Consequently, the total number of shares held in Treasury increased to 302,517,678, which now constitutes 5.02% of the Company's total voting rights.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,717,771,304) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (302,517,678) and its impact on voting rights (5.02%).
- Note that this filing does not contain operational or financial performance data for the period.